Skip to main content
Premium Trial:

Request an Annual Quote

Proteomics International Raises $1.4M

NEW YORK (GenomeWeb) – Proteomics International Laboratories said today it has raised $1.4 million through the placement of 6 million shares of stock at $.24 per share.

The company also announced a share purchase plan for an additional 2 million shares, intending to raise an additional $480,000 at $.24 per share from existing shareholders.

Proteomic International said it will use $500,000 to commercialize its PromarkerD test, a proteomic test for diagnosing and predicting risk of diabetic kidney disease, and another $500,000 to launch an analytical testing services business aimed at the clinical trials market. Both actions will continue to push the company towards cash-flow positive operations, Proteomics International said in a statement.

The balance of the proceeds will be used to fund day-to-day operations.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.